FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 90 filers reported holding FATE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2018 | $1,000 | – | 100 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | -100.0% | 100 | -60.0% | 0.00% | – |
| Q4 2017 | $1,000 | -75.0% | 250 | -80.0% | 0.00% | – |
| Q3 2017 | $4,000 | 0.0% | 1,250 | 0.0% | 0.00% | – |
| Q2 2017 | $4,000 | -20.0% | 1,250 | 0.0% | 0.00% | – |
| Q1 2017 | $5,000 | +25.0% | 1,250 | -28.6% | 0.00% | – |
| Q4 2016 | $4,000 | -60.0% | 1,750 | -46.2% | 0.00% | – |
| Q3 2016 | $10,000 | -23.1% | 3,250 | -58.1% | 0.00% | – |
| Q2 2016 | $13,000 | +85.7% | 7,750 | +93.8% | 0.00% | – |
| Q1 2016 | $7,000 | +133.3% | 4,000 | +300.0% | 0.00% | – |
| Q4 2015 | $3,000 | -25.0% | 1,000 | 0.0% | 0.00% | – |
| Q1 2015 | $4,000 | +33.3% | 1,000 | +42.9% | 0.00% | – |
| Q4 2014 | $3,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,073,190 | $26,599,000 | 26.59% |
| Polaris Venture Management Co. V, L.L.C. | 1,823,186 | $23,391,000 | 24.97% |
| Casdin Capital, LLC | 2,550,000 | $32,717,000 | 5.60% |
| Redmile Group, LLC | 10,359,666 | $132,915,000 | 5.34% |
| Aquilo Capital Management, LLC | 697,096 | $8,944,000 | 4.33% |
| Eversept Partners, LP | 165,000 | $2,116,950 | 1.15% |
| Artal Group S.A. | 2,150,000 | $27,585,000 | 1.02% |
| AlpInvest Partners B.V. | 26,925 | $345,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,654,865 | $21,232,000 | 0.85% |
| Lisanti Capital Growth, LLC | 142,760 | $1,832,000 | 0.74% |